DGAP-News: Neovacs S.A. / Key word(s): Conference Neovacs to present at two major Investor Conferences 30.08.2016 / 08:00 The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE Neovacs to present at two major Investor Conferences The 18th Annual Rodman & Renshaw Global Investment Conference & BIO-Europe 2016 Paris and Boston, August 30, 2016 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that CEO Miguel Sieler will present at both the 18th Annual Rodman & Renshaw Global Investment Conference and BIO-Europe 2016. The Rodman & Renshaw Global Investment Conference, being held September 11- 13 in New York, USA will host over 265 public and private companies and several thousand attendees. The conference will bring together a vast audience of financial and strategic investors with growth companies in the fields of healthcare, natural resources, technology, media, telecommunications, and cleantech. In addition to corporate presentations, the conference facilitates one-on-one meetings with members of the investment community. Miguel Sieler, CEO of Neovacs, will present the company and recent updates at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am EST at the New York Palace Hotel, on the fourth floor in the Louis Room. Neovacs will also present at BIO-Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world's most important meetings for the biotech Industry. This year the BIO-Europe event will draw over 3,500 attendees from 60 countries, representing 1,800 companies. It will provide Neovacs with the opportunity to meet a vast audience of financial and strategic investors, as well as potential high-level partners. About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com Investor Relations / Financial Communication Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com
---------------------------------------------------------------------------
30.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service
---------------------------------------------------------------------------
496637 30.08.2016
---------------------------------------------------------------------------
PRESS RELEASE Neovacs to present at two major Investor Conferences The 18th Annual Rodman & Renshaw Global Investment Conference & BIO-Europe 2016 Paris and Boston, August 30, 2016 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that CEO Miguel Sieler will present at both the 18th Annual Rodman & Renshaw Global Investment Conference and BIO-Europe 2016. The Rodman & Renshaw Global Investment Conference, being held September 11- 13 in New York, USA will host over 265 public and private companies and several thousand attendees. The conference will bring together a vast audience of financial and strategic investors with growth companies in the fields of healthcare, natural resources, technology, media, telecommunications, and cleantech. In addition to corporate presentations, the conference facilitates one-on-one meetings with members of the investment community. Miguel Sieler, CEO of Neovacs, will present the company and recent updates at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am EST at the New York Palace Hotel, on the fourth floor in the Louis Room. Neovacs will also present at BIO-Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world's most important meetings for the biotech Industry. This year the BIO-Europe event will draw over 3,500 attendees from 60 countries, representing 1,800 companies. It will provide Neovacs with the opportunity to meet a vast audience of financial and strategic investors, as well as potential high-level partners. About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com Investor Relations / Financial Communication Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com
---------------------------------------------------------------------------
30.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service
---------------------------------------------------------------------------
496637 30.08.2016
